SG10201406300YA - L-ornithine phenyl acetate and methods of making thereof - Google Patents
L-ornithine phenyl acetate and methods of making thereofInfo
- Publication number
- SG10201406300YA SG10201406300YA SG10201406300YA SG10201406300YA SG10201406300YA SG 10201406300Y A SG10201406300Y A SG 10201406300YA SG 10201406300Y A SG10201406300Y A SG 10201406300YA SG 10201406300Y A SG10201406300Y A SG 10201406300YA SG 10201406300Y A SG10201406300Y A SG 10201406300YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- phenyl acetate
- making
- ornithine phenyl
- forms
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 229940049953 phenylacetate Drugs 0.000 abstract 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, some embodiments, in be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-omithine phenyl acetate. Figure 1 -77-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16667609P | 2009-04-03 | 2009-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406300YA true SG10201406300YA (en) | 2015-01-29 |
Family
ID=42828717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011071164A SG174982A1 (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
| SG10202010988WA SG10202010988WA (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
| SG10201406300YA SG10201406300YA (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011071164A SG174982A1 (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
| SG10202010988WA SG10202010988WA (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8173706B2 (en) |
| EP (4) | EP2413924B1 (en) |
| JP (6) | JP6144488B2 (en) |
| KR (6) | KR102217081B1 (en) |
| CN (3) | CN102421432B (en) |
| AU (1) | AU2010232521B2 (en) |
| BR (1) | BRPI1013657A2 (en) |
| CA (5) | CA3077846C (en) |
| CY (1) | CY1119843T1 (en) |
| DK (3) | DK3686183T3 (en) |
| EA (2) | EA023051B1 (en) |
| ES (3) | ES2652187T3 (en) |
| HK (1) | HK1248558A1 (en) |
| HR (2) | HRP20221232T8 (en) |
| HU (2) | HUE060371T2 (en) |
| IL (2) | IL215449B (en) |
| LT (2) | LT2413924T (en) |
| MX (3) | MX2011010262A (en) |
| NO (1) | NO2413924T3 (en) |
| NZ (3) | NZ595706A (en) |
| PL (2) | PL2413924T3 (en) |
| PT (2) | PT3686183T (en) |
| SG (3) | SG174982A1 (en) |
| SI (1) | SI2413924T1 (en) |
| WO (1) | WO2010115055A1 (en) |
| ZA (1) | ZA201107189B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2153870E (en) | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| EA023051B1 (en) | 2009-04-03 | 2016-04-29 | Осера Терапьютикс, Инк. | Crystalline forms of l-ornithine phenyl acetate and use thereof |
| EP2799067B1 (en) | 2009-06-08 | 2019-04-03 | UCL Business PLC | Treatment of brain inflammation using L-Ornithine Phenylacetate |
| US8068011B1 (en) | 2010-08-27 | 2011-11-29 | Q Street, LLC | System and method for interactive user-directed interfacing between handheld devices and RFID media |
| BR112013008054B1 (en) * | 2010-10-06 | 2019-04-09 | Ocera Therapeutics, Inc. | COMPOSITION AND PROCESS FOR PRODUCTION OF L-ORNITINE PHENYL ACETATE SALT |
| CN102993037B (en) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | Preparation method of L-ornithine phenylacetate |
| CN105481725B (en) * | 2014-09-18 | 2019-01-22 | 博瑞生物医药（苏州）股份有限公司 | The crystal form and preparation method thereof of L-arginine phenylacetate |
| BR112017010761B1 (en) | 2014-11-24 | 2022-10-18 | Ucl Business Plc | TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STARTED CELL ACTIVATION WITH THE USE OF AMMONIA REDUCTION THERAPIES |
| CA2983146C (en) * | 2015-04-20 | 2023-09-12 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| EP3352748A4 (en) * | 2015-09-25 | 2019-06-05 | Ocera Therapeutics, Inc. | Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| CN113768863A (en) * | 2015-11-13 | 2021-12-10 | 欧塞拉治疗有限公司 | L-ornithine phenylacetate formulations |
| US11219611B2 (en) * | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
| JP7126520B2 (en) * | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス， インコーポレイテッド | Method for producing L-ornithine phenylacetate |
| JP7266581B2 (en) | 2017-08-14 | 2023-04-28 | アクセラ・ヘルス・インコーポレイテッド | Amino acid composition for treatment of liver disease |
| US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| CN110707221B (en) * | 2019-09-25 | 2023-09-01 | 北京大学深圳研究生院 | Application of amino acid ionic liquid in preparation of perovskite layer in perovskite photoelectric device |
| BR112022007268A2 (en) * | 2019-10-16 | 2022-07-05 | Ocera Therapeutics Inc | DOSAGE AND USES OF ORNITINE PHENYLACTATE FOR THE TREATMENT OF HYPERAMMONEMIA |
| WO2023240081A1 (en) * | 2022-06-06 | 2023-12-14 | Yale University | Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (en) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100161A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| JP2522034B2 (en) * | 1988-12-27 | 1996-08-07 | 味の素株式会社 | α-Keto acid / amino acid salt compound and method for producing the same |
| JPH03273578A (en) | 1990-03-23 | 1991-12-04 | Ricoh Co Ltd | Objective lens cleaning device |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| DE4020980C1 (en) * | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| JP3127484B2 (en) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | Hepatitis treatment |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| CA2144163A1 (en) | 1992-09-09 | 1994-03-17 | Fisons Limited | Pharmaceutical packaging |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (en) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | Method for producing salt of ornithine with acidic amino acids or keto acids |
| US5856481A (en) | 1994-07-28 | 1999-01-05 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| AU2251897A (en) | 1996-02-13 | 1997-09-02 | Trustees Of The University Of Pennsylvania, The | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| AU4778700A (en) | 1999-05-21 | 2000-12-12 | Takeda Chemical Industries Ltd. | Liver function controlling agents |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (en) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | Pharmaceutical granule preparation containing branched-chain amino acid and method for producing the same |
| JPWO2002074302A1 (en) | 2001-03-15 | 2005-07-14 | 独立行政法人理化学研究所 | Amino acid composition for improving liver dysfunction |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| CN1383815A (en) | 2002-05-08 | 2002-12-11 | 刘万忠 | Compound prepn of ornithine and asparagic acid for preventing and treating hepatosis and hepatic encephalopathy and its prepn process |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| WO2004019928A1 (en) | 2002-08-30 | 2004-03-11 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) * | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (en) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compounds for reducing hyperammonemia in patients having cirrhosis or any inability for eliminating ammonium. |
| JP5064037B2 (en) * | 2004-02-23 | 2012-10-31 | ジェネンテック， インコーポレイテッド | Heterocyclic self-destructive linkers and conjugates |
| JP4954867B2 (en) * | 2004-05-06 | 2012-06-20 | オステオロジックス エイ／エス | High-yield and rapid synthesis for the production of organometallic salts |
| US20060045912A1 (en) | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| PT2153870E (en) | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| WO2007058634A1 (en) | 2005-11-17 | 2007-05-24 | Diagen Smartno Pri Ljubljani, D.O.O. | Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| EA023051B1 (en) | 2009-04-03 | 2016-04-29 | Осера Терапьютикс, Инк. | Crystalline forms of l-ornithine phenyl acetate and use thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| EP2799067B1 (en) | 2009-06-08 | 2019-04-03 | UCL Business PLC | Treatment of brain inflammation using L-Ornithine Phenylacetate |
| JP2011236160A (en) | 2010-05-11 | 2011-11-24 | Shinshu Univ | Medicine for treating nonalcoholic hepatic disease |
| BR112013008054B1 (en) | 2010-10-06 | 2019-04-09 | Ocera Therapeutics, Inc. | COMPOSITION AND PROCESS FOR PRODUCTION OF L-ORNITINE PHENYL ACETATE SALT |
| SI2922576T1 (en) | 2012-11-21 | 2018-04-30 | Horizon Therapeutics, Llc | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| BR112017010761B1 (en) | 2014-11-24 | 2022-10-18 | Ucl Business Plc | TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STARTED CELL ACTIVATION WITH THE USE OF AMMONIA REDUCTION THERAPIES |
| CA2983146C (en) | 2015-04-20 | 2023-09-12 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
-
2010
- 2010-04-01 EA EA201171216A patent/EA023051B1/en not_active IP Right Cessation
- 2010-04-01 KR KR1020207016586A patent/KR102217081B1/en active IP Right Grant
- 2010-04-01 ES ES10759442.6T patent/ES2652187T3/en active Active
- 2010-04-01 JP JP2012503725A patent/JP6144488B2/en active Active
- 2010-04-01 DK DK20161306.4T patent/DK3686183T3/en active
- 2010-04-01 LT LTEP10759442.6T patent/LT2413924T/en unknown
- 2010-04-01 EP EP10759442.6A patent/EP2413924B1/en active Active
- 2010-04-01 EP EP22185562.0A patent/EP4101838A1/en active Pending
- 2010-04-01 HR HRP20221232TT patent/HRP20221232T8/en unknown
- 2010-04-01 BR BRPI1013657A patent/BRPI1013657A2/en not_active Application Discontinuation
- 2010-04-01 DK DK10759442.6T patent/DK2413924T3/en active
- 2010-04-01 CA CA3077846A patent/CA3077846C/en active Active
- 2010-04-01 PL PL10759442T patent/PL2413924T3/en unknown
- 2010-04-01 PL PL20161306.4T patent/PL3686183T3/en unknown
- 2010-04-01 SG SG2011071164A patent/SG174982A1/en unknown
- 2010-04-01 CN CN201080021311.6A patent/CN102421432B/en active Active
- 2010-04-01 ES ES20161306T patent/ES2928586T3/en active Active
- 2010-04-01 MX MX2011010262A patent/MX2011010262A/en active IP Right Grant
- 2010-04-01 NO NO10759442A patent/NO2413924T3/no unknown
- 2010-04-01 MX MX2020009699A patent/MX2020009699A/en unknown
- 2010-04-01 NZ NZ595706A patent/NZ595706A/en unknown
- 2010-04-01 AU AU2010232521A patent/AU2010232521B2/en active Active
- 2010-04-01 NZ NZ708458A patent/NZ708458A/en unknown
- 2010-04-01 CA CA2998434A patent/CA2998434C/en active Active
- 2010-04-01 CN CN201410392027.XA patent/CN104230730B/en active Active
- 2010-04-01 WO PCT/US2010/029708 patent/WO2010115055A1/en active Application Filing
- 2010-04-01 SG SG10202010988WA patent/SG10202010988WA/en unknown
- 2010-04-01 NZ NZ619235A patent/NZ619235A/en unknown
- 2010-04-01 CA CA2757373A patent/CA2757373C/en active Active
- 2010-04-01 DK DK17185173.6T patent/DK3263100T3/en active
- 2010-04-01 PT PT201613064T patent/PT3686183T/en unknown
- 2010-04-01 PT PT107594426T patent/PT2413924T/en unknown
- 2010-04-01 CA CA2998344A patent/CA2998344C/en active Active
- 2010-04-01 CA CA3205755A patent/CA3205755A1/en active Pending
- 2010-04-01 CN CN201710053850.1A patent/CN106810464B/en active Active
- 2010-04-01 SG SG10201406300YA patent/SG10201406300YA/en unknown
- 2010-04-01 EP EP20161306.4A patent/EP3686183B1/en active Active
- 2010-04-01 MX MX2014008993A patent/MX356608B/en unknown
- 2010-04-01 KR KR1020117026256A patent/KR101844605B1/en active IP Right Grant
- 2010-04-01 SI SI201031596T patent/SI2413924T1/en unknown
- 2010-04-01 LT LTEP20161306.4T patent/LT3686183T/en unknown
- 2010-04-01 HU HUE20161306A patent/HUE060371T2/en unknown
- 2010-04-01 ES ES17185173T patent/ES2791524T3/en active Active
- 2010-04-01 HU HUE10759442A patent/HUE035921T2/en unknown
- 2010-04-01 KR KR1020217004211A patent/KR102399540B1/en active IP Right Grant
- 2010-04-01 KR KR1020227016294A patent/KR20220067001A/en active IP Right Grant
- 2010-04-01 EA EA201500650A patent/EA034409B1/en not_active IP Right Cessation
- 2010-04-01 EP EP17185173.6A patent/EP3263100B1/en active Active
- 2010-04-01 KR KR1020197012203A patent/KR102123243B1/en active IP Right Grant
- 2010-04-01 KR KR1020187008530A patent/KR101975726B1/en active IP Right Grant
- 2010-04-02 US US12/753,763 patent/US8173706B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 ZA ZA2011/07189A patent/ZA201107189B/en unknown
- 2011-10-02 IL IL215449A patent/IL215449B/en active IP Right Grant
-
2012
- 2012-03-30 US US13/436,642 patent/US8492439B2/en active Active
-
2013
- 2013-07-08 US US13/937,107 patent/US8785498B2/en active Active
-
2014
- 2014-06-09 US US14/299,940 patent/US9034925B2/en active Active
-
2015
- 2015-02-20 JP JP2015031199A patent/JP6010154B2/en active Active
- 2015-05-18 US US14/715,481 patent/US9604909B2/en active Active
-
2016
- 2016-12-07 JP JP2016237164A patent/JP6328737B2/en active Active
-
2017
- 2017-03-24 US US15/469,359 patent/US10173964B2/en active Active
- 2017-12-19 HR HRP20171962TT patent/HRP20171962T1/en unknown
- 2017-12-20 CY CY20171101334T patent/CY1119843T1/en unknown
-
2018
- 2018-04-18 JP JP2018079490A patent/JP6647336B2/en active Active
- 2018-06-27 HK HK18108291.9A patent/HK1248558A1/en unknown
- 2018-07-17 US US16/037,655 patent/US10550069B2/en active Active
- 2018-12-18 IL IL263784A patent/IL263784A/en unknown
-
2020
- 2020-01-14 JP JP2020003346A patent/JP7086118B2/en active Active
- 2020-01-31 US US16/778,696 patent/US11161802B2/en active Active
-
2021
- 2021-11-01 US US17/516,591 patent/US20220162155A1/en active Pending
-
2022
- 2022-03-25 JP JP2022049427A patent/JP2022088504A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201406300YA (en) | L-ornithine phenyl acetate and methods of making thereof | |
| WO2009099719A3 (en) | Compositions and methods for the treatment of tumor of hematopoietic origin | |
| WO2010062863A3 (en) | Compositions containing satiogens and methods of use | |
| MY155564A (en) | Arginine salts and their uses for the treatment of illnesses in the oral cavity | |
| MX2013009175A (en) | Compositions comprising peroxy î±-ketocarboxylic acid and methods for producing and using the same. | |
| MX2019008122A (en) | Heterocycle amines and uses thereof. | |
| MX2010008943A (en) | Rebaudioside a derivative products and methods for making. | |
| IL209188A (en) | Sweetener, compositions comprising the same and methods of producing the same | |
| IL211541A0 (en) | Co-crystal compositions, methods of producing the same and uses thereof | |
| MY152437A (en) | Oral care compositions | |
| UA102858C2 (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof | |
| EP2320740A4 (en) | Pharmaceutical compositions and methods for producing low impurity concentrations of the same | |
| MX2009013515A (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics. | |
| HK1198929A1 (en) | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same 34- | |
| MX342947B (en) | Treatment of type 2 diabetes. | |
| IN2014CN02970A (en) | ||
| BR112012016054A2 (en) | Nutritional compositions comprising fruit flakes including docosahexaenoic acid | |
| EP2709455A4 (en) | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives | |
| MX344189B (en) | Formulations of mazindol. | |
| WO2011037712A3 (en) | Nutritional compositions including theanine and exogenous nucleotides | |
| WO2011103586A3 (en) | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine | |
| WO2012018980A3 (en) | Compositions and methods for treating inflammatory diseases | |
| WO2012087434A3 (en) | Use of phosphoric acid for treating cardiovascular disorders | |
| WO2014145086A3 (en) | Products and methods using lunasin-enriched soy extract mixtures | |
| OKUYAMA | I Look Forward to the Days of Discovering New Findings |